Overcoming immune suppression and rebalancing the immune response in ovarian cancer
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
We will try to find and reverse immune suppression by analyzing bone marrow, blood, spleen, peritoneal fluid, and tumor samples from women having surgery for ovarian cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Gynaecologisch Oncologisch Centrum Zuid Academic / other |
| Drugs / interventions | chemotherapy, Immunotherapy |
| Locations | 1 site (Eindhoven, North Brabant) |
| Trial ID | NCT06611072 on ClinicalTrials.gov |
What this trial studies
This translational project collects bone marrow, blood, peritoneal fluid, spleen, and tumor biopsies from women with newly diagnosed ovarian cancer undergoing primary or interval debulking, alongside control samples from women having benign gynecologic surgery. Researchers will profile myeloid progenitor cells and other immune cell populations to map tumor-induced changes in the bone marrow and tumor microenvironment. Ex vivo experiments will test whether nanoparticles or other agents can modify these cells to reduce immune suppression. The goal is to identify immune mechanisms and potential targets that could inform new immunotherapy strategies for ovarian cancer.
Who should consider this trial
Good fit: Women aged 18 or older with newly diagnosed ovarian cancer who are scheduled for primary or interval debulking surgery and able to provide informed consent.
Not a fit: Pregnant or breastfeeding women, people with active infections or known immunosuppressive conditions, those taking immunomodulatory medications, or those with severe comorbidities are excluded and unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the work could reveal new ways to reverse tumor-driven immune suppression and point to therapies that improve responses and survival in ovarian cancer patients.
How similar studies have performed: Related approaches have shown promising preclinical and laboratory results, but clinical benefit from reprogramming myeloid cells in ovarian cancer has not yet been established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects should be at least 18 years old and mentally competent; * Newly diagnosed patients with OC who go for primary debulking surgery or patients with OC who are scheduled for interval debulking; * Controls: women who undergo surgery for benign gynaecological conditions under general anaesthesia. Exclusion Criteria: * Mentally incompetent; * Pregnant or breastfeeding; * Known inflammatory of infectious diseases or an immunosuppressive status; * Using medication interfering with the immune system; * Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas); * Serious psychiatric pathology; * A self reported alcohol consumption of \>21 units per week.
Where this trial is running
Eindhoven, North Brabant
- Catharina Hospital — Eindhoven, North Brabant, Netherlands (Recruiting)
Study contacts
- Study coordinator: Jurgen Piek, MD, PhD
- Email: jurgen.piek@catharinaziekenhuis.nl
- Phone: 00310402399300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.